NT-proBNP levels predict mortality in patients with acute decompensated and de novo heart failure: Study
Korea: The levels of NT-pro B-type natriuretic peptide (NT-proBNP) are an important prognostic factor for both de novo heart failure (DNHF) and acute decompensated chronic heart failure (ADHF), says a study published in the International Journal of Cardiology.
Patients with ADHF has consistently higher risks for 1-year all-cause mortality with the same NT-proBNP level compared to those with DNHF, the authors noted.
Previous studies have shown NT-proBNP to be a powerful prognostic factor for acute heart failure. Se-Eun Kim, Yonsei University College of Medicine, Seoul, Republic of Korea, and colleagues aimed to examine whether NT-proBNP levels differ based on the type of heart failure present.
Patients were categorized into two groups DNHF (n = 1617) and ADHF (n=1212) using a prospective, multicenter cohort, the Korean Acute Heart Failure Registry. Measurement of NT-proBNP levels was done on admission. All-cause mortality was the primary outcome and secondary outcomes were re-hospitalization for heart failure and a composite of all-cause mortality or re-hospitalization for heart failure at 90 days and 1 year.
Based on the findings, the researchers reported the following findings:
- NT-proBNP levels were significantly lower in patients with DNHF than in those with ADHF (median 4213 vs. 5523 ng/L).
- Compared to patients with DNHF, patients with ADHF had a significantly worse prognosis for 1-year all-cause mortality (adjusted hazard ratio (HR) = 1.46).
- A higher NT-proBNP level was associated with higher 1-year all-cause mortality for both heart failure types (adjusted HR = 2.00 in ADHF; adjusted HR = 2.41 in DNHF).
- All-cause mortality risk was always higher in patients with ADHF than in those with DNHF for any given NT-proBNP level.
The authors conclude, "NT-proBNP had an important role as a prognostic factor in both DNHF and ADHF. However, as time passed ADHF had poorer outcomes than DNHF." "ADHF patients had higher risks than DNHF patients at any level of NT-proBNP."
Reference:
Kim SE, Cho DH, Son JW, Kim JY, Kang SM, Cho MC, Lee HY, Choi DJ, Jeon ES, Yoo BS. Impact of NT-proBNP on prognosis of acute decompensated chronic heart failure versus de novo heart failure. Int J Cardiol. 2022 Jun 23:S0167-5273(22)01007-5. doi: 10.1016/j.ijcard.2022.06.055. Epub ahead of print. PMID: 35753618.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.